BigOmics Analytics’ Post

A successful preclinical study is the result of a well planned study design, from model selection to data analysis. Lumin was created to improve our clients' oncology research programs success through robust model selection and faster advanced data analysis. Our unique software solution integrates Champions’ tumor model multi-omic data and public datasets in one accessible platform for model selection and data interpretation. Make data-driven decisions with confidence: access all of Champions' proprietary, highly characterized PDX datasets and leverage our state-of the art data analytics tools and visualizations. Get your FREE 14-Day Trial and start exploring Lumin today: https://hubs.li/Q02dQK1L0 #bioinformatics #cancerresearch #multi-omics #Lumin #Freetrial #modelselection #dataanalysis #studydesign #PDX

Welcome Andrew Lo to the n-Lorem Board of Directors. His expertise in creating novel economic models that provide solutions for cost of care for rare illnesses could open the door for more nano-rare patients to receive treatment. Andrew is a co-founder of BridgeBio Pharma, QLS Advisors, Quantile Health, and Uncommon Cures; a director of AbCellera, Atomwise, BridgeBio, Uncommon Cures, and Vesalius; and a member of the advisory board to the American Cancer Society’s BrightEdge Impact Fund. His healthcare-related research interests include: new financial engineering tools and business models for drug and device development and healthcare delivery, especially for rare and ultra-rare diseases; statistical methods for incorporating patient preferences into the drug approval process; predicting clinical trial outcomes via machine learning techniques; and novel reimbursement models for creating a robust gene and cell therapy ecosystem. https://lnkd.in/gMSvtV-H

📢 Join FOx Biosystems for an upcoming webinar to explore an innovative one-step automated method for affinity-specific detection, quantification, and isolation of extracellular vesicles (EVs), advancing EV-based biomarker development in disease and therapy research. Current methods for EV purification and quantification are slow, biased, and costly. This webinar will showcase a new label-free fiber-optic method that’s faster, automated, and highly specific. 🌟 The expert speakers will present proof-of-concept data and discuss how this method could enhance diagnostics, improve early detection, and reduce cancer mortality and healthcare costs. REGISTER HERE: https://buff.ly/4gP5Jo7 #Biotech #Biomarkers #ClinicalLaboratory #Diagnostics #LaboratoryTesting #LaboratoryTechnology #ExtracellularVesicles #LaboratoryManagement

✨ ✨ ✨ I'd like to kick off a new series highlighting some of the best and brightest across the Life Science space ✨ ✨ ✨   My first instalment of this kicks off with a company doing incredible work in the Drug Design space... 🥁 🥁   Exscientia   🔎 They utilise precision information derived from patient tissues alongside sophisticated AI technology to source optimised drug profiles for research. This integrated system has been the first to demonstrate improved clinical outcomes in oncology, and I believe that is just the beginning in their revolution.   📈 They currently have four targets at pre clinical, and phase 1-2, across Haematology, Oncology, and Inflammatory Diseases. With 40% of total clinical growth within Biotech/ Pharmaceuticals sitting within Oncology in 2023, Exscientia should be on your radar!   🗞 With the recent appointment of Marie-Louise Fjaellskog, and promotion of John Overington, I can't wait to see the continued success of this truly pioneer company. #Biotech #innovation #AI #DrugDesign

🧬 Guess what. You’re probably missing a hidden world of insights in your sequencing data… There’s game-changing information just waiting to be discovered, and it is already advancing drug discovery, biotech innovation, and disease studies. If you’ve not considered analyzing the ‘dark genome,’ you’re losing out. Transposable elements (TEs) are critical players in this hidden world and are fundamental to health and cancer. 🔗 Find out more in our article: https://lnkd.in/dP_-AHs6 🚀 While analyses of the dark genome might be challenging, Nexco Analytics can help. We’re experts in dark genome analyses here to help you leverage your data to the fullest. #sequencing #biotech #pharma #bioinformatics

🚀 Today is the day! The Cydem VT from Beckman Coulter Life Sciences has been revealed! The Cydem VT Automated Cell Culture System is a cutting-edge platform that integrates multiple Beckman Coulter Life Sciences technologies to streamline and enhance cell line development. Lab managers can now benefit from a higher-throughput method for top clone screening, ensuring that no promising clones are overlooked in the critical process of consistently selecting the best. New therapeutic antibodies for cancer and autoimmune diseases can now be discovered more quickly with this new system, revolutionizing how labs approach breakthrough research. As part of the team, I had the privilege of helping design and build the software that powers this advanced system. 💻 It's exciting to see how the platform will transform workflows, offering increased confidence in results. The key technologies behind this innovation include: - Biomek workstation - Biolector XT Microbioreactor - Vi-Cell Blu Cell Counter - Valita Titer Assay Check out more details on Beckman Coulter’s official website: https://lnkd.in/gs2vrvYJ Plus, there’s a great tutorial video that dives into how the product works. 🔬 #biomek #beckmancoulter #celllinedevelopment #cellculture #bioreactor

What a great evolution of a solution for cell culture.

🔬 Illumina announces $750 million credit agreement with J.P. Morgan 🔬 Illumina, a leading player in the genomic sequencing industry, has just announced a significant financial milestone. The company has secured a $750 million credit agreement with JP Morgan, aimed at supporting the divestment of its subsidiary, GRAIL. This strategic financial move is expected to strengthen Illumina’s financial position and facilitate the growth and development of its core genomic technologies. Grail, known for its groundbreaking early cancer detection technology, will benefit from this divestment as it continues to innovate and expand its impact on healthcare. This is great news from Illumina and JP Morgan, demonstrating strong confidence in the future of genomic health and personalized medicine. #genomics #Illumina #grail #genomicsequencing #biotech

The clinical NGS landscape continues to evolve, and the latest edition of our NGS DxBook offers insights into changes in the competitive landscape. Focusing on the use of #Illumina and #ThermoFisher platforms and assays in clinical oncology, Rishikesh noticed a few interesting trends since last year: 1. Diversity and Dominance in Gene Panels: Illumina leads in panel diversity and volume, leveraging an expansive range of third-party kits. Our data visualizes this dominance across various panel sizes including WES and WGS, and the impressive traction these approaches have gained in recent years. 2. Regional Dynamics and Market Shares: While ThermoFisher has carved a niche in smaller gene panels (1-52 genes), especially in Europe, Illumina continues to expand its footprint in larger panels, with a dominant position in the U.S. 3. Strategic Positions in a Competitive Field: Despite challenges in the stock market, Illumina's strategic partnerships with reagent and bioinformatics firms like Pillar and Velsera has solidified its entrenched market position, simplifying workflows and enhancing user experiences. Conversely, ThermoFisher’s investment in an integrated ecosystem with solutions like Ion Chef and Ion Reporter caters to labs seeking end-to-end automation. Feel free to reach out with questions! And remember: #NGSisUnstoppable

📰 In the Summer 2024 edition of Drug Discovery World, Diana Spencer examines the most recent advancements in high-throughput screening technologies for drug discovery and their potential to expedite therapeutic development: https://ow.ly/cnIH50Stkl3. During her discussion with Shan D., Vice President of Strategy and Innovation at Molecular Devices, Shan emphasizes the significance of automated cell culture and how our CellXpress.ai Automated Cell Culture System offers a solution for researchers that incorporates machine learning to enhance processes like media exchange, plating, passaging, organoid monitoring, endpoint assays, and complex image analysis—ultimately increasing both productivity and reproducibility in drug screening. #3dbiology #3dcellculture #organoids #drugdiscovery #drugscreening #drugdevelopment #diseasemodeling #labautomation #ai #machinelearning #deeplearning #highcontentimaging #highcontentscreening #scienceandtechnology #pharma #geneeditting #cellculture #pdo #imageanalysis #IntheNews